G1 Therapeutics, Inc.
GTHXDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Trilaciclib
TNBC - Triple-Negative Breast Cancer
Carboplatin
Small Cell Lung Cancer
G1T38
Carcinoma, Non-Small-Cell Lung
Cylophosphamide
Triple Negative Breast Cancer
Etoposide
Small Cell Lung Cancer
Topotecan
Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Trilaciclib | Phase 3 | TNBC - Triple-Negative Breast Cancer | - | - |
Carboplatin | Phase 3 | Small Cell Lung Cancer | - | - |
G1T38 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Cylophosphamide | Phase 2 | Triple Negative Breast Cancer | - | - |
Etoposide | Phase 2 | Small Cell Lung Cancer | - | - |
Topotecan | Phase 2 | Small Cell Lung Cancer | - | - |
Small Cell Lung Cancer
3 drugs in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Triple Negative Breast Cancer
1 drug in this indication
TNBC - Triple-Negative Breast Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)